CT 32228 is an inhibitor of LPAAT-beta. It effectively suppresses tumor cell proliferation and has an IC50 ranging from 0.1 to 0.8 µM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. When used in combination with Rituximab, it promotes apoptosis. In vivo studies demonstrate that CT 32228 can delay xenograft tumor growth by 50%. This compound is applicable in research related to acute leukemia.
Molekulargewicht:
390.67
CAS Nummer:
[521064-34-6]
Formel:
C16H13BrClN5
Target-Kategorie:
Apoptosis
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
